NCT03004131

MP-AzeFlu Allergen Chamber - Onset of Action Study

Clinical Trial to Assess Onset of Action of Azelastine Hydrochloride and Fluticasone Propionate Nasal Spray Delivered in a Single Spray (MP-AzeFlu) in the Treatment of Allergen-Induced Allergic Rhinitis Symptoms in Comparison to Placebo and Free Combination of Fluticasone Propionate Nasal Spray and Oral Loratadine

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 82 (actual)
• Sponsor: MEDA Pharma GmbH & Co. KG · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Not accepted

Summary

This study is to assess the onset of action of fixed drug combination of azelastine hydrochloride and fluticasone propionate nasal spray (MP-AzeFlu) in treating the nasal symptoms of seasonal allergic rhinitis (SAR) induced by an allergen challenge in an Environmental Exposure Chamber (EEC).

Conditions

• Seasonal Allergic Rhinitis

Interventions

Type	Name	Description
DRUG	Azelastine hydrochloride + fluticasone propionate nasal spray
DRUG	Placebos
DRUG	fluticasone propionate nasal spray + loratadine

Timeline

• Start date: 2017-01-07
• Primary completion: 2017-03-29
• Completion: 2017-03-29
• First posted: 2016-12-28
• Last updated: 2022-02-22

Locations

1 site across 1 country: Canada